Whole exome and targeted deep sequencing identify genome-wide allelic loss and frequent SETDB1 mutations in malignant pleural mesotheliomas. [PDF]
, 2016 Malignant pleural mesothelioma (MPM), a rare malignancy with a poor prognosis, is mainly caused by exposure to asbestos or other organic fibers, but the underlying genetic mechanism is not fully understood.
Fang, Li Tai +11 more
core +3 more sources
Estimating past inhalation exposure to asbestos: a tool for risk attribution and disease screening [PDF]
, 2017 Introduction: Late presentation is common in mesothelioma. Reliable assessment of past exposure to asbestos is a necessary first step for risk attribution and for the development of a future screening programme. Such a programme could maximise access
Blyth, Kevin G. +2 more
core +1 more source
Orphanet Journal of Rare Diseases, 2008 Malignant mesothelioma is a fatal asbestos-associated malignancy originating from the lining cells (mesothelium) of the pleural and peritoneal cavities, as well as the pericardium and the tunica vaginalis.
Parker Robert J +2 more
doaj +1 more source
Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future
Frontiers in Oncology, 2020 Malignant pleural mesothelioma (MPM) is a rare, aggressive cancer of the pleural surface associated with asbestos exposure. The median survival of MPM patients is a mere 8–14 months, and there are few biomarkers and no cure available.
F. Nicolini +6 more
semanticscholar +1 more source
SYSTEMS-2: a randomised phase II study of radiotherapy dose escalation for pain control in malignant pleural mesothelioma [PDF]
, 2018 SYSTEMS-2 is a randomised study of radiotherapy dose escalation for pain control in 112 patients with malignant pleural mesothelioma (MPM). Standard palliative (20Gy/5#) or dose escalated treatment (36Gy/6#) will be delivered using advanced radiotherapy ...
Alexander, L. +11 more
core +2 more sources
Nature Communications, 2019 Malignant pleural mesothelioma (MPM) is recognized as heterogeneous based both on histology and molecular profiling. Histology addresses inter-tumor and intra-tumor heterogeneity in MPM and describes three major types: epithelioid, sarcomatoid and ...
Y. Blum +19 more
semanticscholar +1 more source
Emerging Treatments for Malignant Pleural Mesothelioma: Where Are We Heading?
Frontiers in Oncology, 2020 Malignant pleural mesothelioma (MPM) is an uncommon but aggressive and treatment resistant neoplasm with low survival rates. In the last years we assisted to an exponential growth in the appreciation of mesothelioma pathobiology, leading several new ...
L. Cantini +3 more
semanticscholar +1 more source
In Vitro and in vivo anti-tumoral effects of the flavonoid apigenin in malignant mesothelioma [PDF]
, 2017 Malignant mesothelioma (MM) is a tumor arising from mesothelium. MM patients' survival is poor. The polyphenol 4',5,7,-trihydroxyflavone Apigenin (API) is a "multifunctional drug". Several studies have demonstrated API anti-tumoral effects.
Andrea Modesti +13 more
core +2 more sources
A comparison of the results from intra-pleural and intra-peritoneal studies with those from inhalation and intratracheal tests for the assessment of pulmonary responses to inhalable dusts and fibres. [PDF]
, 2016 The aim of this paper is to compare results from inhalation studies with those from intraperitoneal and intrapleural tests, where available, for a number of fibrous and particulate test materials.
Bevan, Ruth +2 more
core +2 more sources
Is Adenosine Deaminase in Pleural Fluid a Useful Marker for Differentiating Tuberculosis from Lung Cancer or Mesothelioma in Japan, a Country with Intermediate Incidence of Tuberculosis? [PDF]
, 2011 The objective of this study was to evaluate the utility of the determination of adenosine deaminase (ADA) level in pleural fluid for the differential diagnosis between tuberculous pleural effusion (TPE) and malignant pleural effusion (MPE) in Japan, a ...
Aoe, Keisuke +9 more
core +1 more source